Results 221 to 230 of about 159,586 (333)

Recent improvement in clinical pancreas transplantation [PDF]

, 1987
Abendroth, D., Illner, Wolf-Dieter, Land, Walter, Landgraf, R., Schleibner, S.   +4 more
core   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada, Mary P. Choules, Frances A. Brightman, Shigeru Takeshita, Shinsuke Nakao, Nobuaki Amino, Takeshi Nakayama, Masato Takeuchi, Kanji Komatsu, Fernando Ortega, Hitesh Mistry, David Orrell, Christophe Chassagnole, Peter L. Bonate   +13 more
wiley   +1 more source

Toward next-generation therapeutic HPV vaccines: A review on expanding the antigen repertoire and an integrated bioinformatics selection framework. [PDF]

Hum Vaccin Immunother
Zhang D, Guo S, Yuan J, Hu Y, Li K, Han Y.   +5 more
europepmc   +1 more source

Molecular biology of the mouse Q region [PDF]

, 1987
A. Eastman O'Neill, A. Winoto, A.-M. Lew, A.L. Mellor, A.L. Mellor, A.L. Mellor, C. Jaulin, C.G. Miyada, D. Cosman, D. Cosman, D. Stephan, D.A. Fisher, D.H. Schulze, D.S. Straus, E.H. Weiss, E.H. Weiss, E.H. Weiss, Elisabeth H. Weiss, F. Bregegere, I. Stroynowski, J. Geliebter, J. Klein, J. Michaelson, J. Stroynowski, J.H. Rogers, J.H. Rogers, J.J. Devlin, J.J. Devlin, J.L. Lalanne, J.L. Lalanne, L. Flaherty, L. Flaherty, L.R. Pease, M. Kress, M. Steinmetz, M. Steinmetz, R.A. Flavell, R.A. Flavell, R.S. Goodenow, S.G. Nathenson, W.L. Maloy, Y. Obata   +41 more
core   +1 more source

Histocompatibility antigens controlled by the I region of the murine H-2 complex. II. K/D region compatibility is not required for I-region cell-mediated lymphocytotoxicity. [PDF]

, 1977
J Klein, Chinlee Chiang, V Hauptfeld
openalex   +1 more source

Harnessing Natural Compounds in Psoriasis: Targeting Cellular Pathways for Effective Therapy

Phytotherapy Research, EarlyView.
Natural compounds act on key cellular pathways in psoriasis by suppressing keratinocyte hyperproliferation, modulating Th17/IL‐17‐mediated immune responses, and reducing oxidative stress. These multi‐target effects highlight their potential as safer adjunctive therapies alongside conventional treatments.
Hye Jin Lee, Yu Jin So, Il‐Joo Jo, Ji Yong Jang, Tae Han Yook, Jun Ho Lee, Sung Wook Kim, Kangwook Lee, Soo Jung Park, Gabsik Yang   +9 more
wiley   +1 more source

The Antigen Presenting Capabilities of Group 3 Innate Lymphoid Cells: Insights Into Immunogenic or Tolerogenic Outcomes for T Cells. [PDF]

Eur J Immunol
Calabrò A, Yamazaki S, Ferlazzo G, Campana S.   +3 more
europepmc   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

Anti-GBM disease after nephrectomy for xanthogranulomatous pyelonephritis in a patient expressing HLA DR15 major histocompatibility antigens: a case report. [PDF]

Clin Nephrol Case Stud, 2015
O'Hagan E, Mallett T, Convery M, McKeever K.   +3 more
europepmc   +1 more source

Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing

Small, EarlyView.
The review highlights nature‐inspired nanocarriers for CRISPR delivery, emphasizing viral vectors, extracellular vesicles, liposomes, and lipid nanoparticles. It discusses their roles in improving specificity, minimizing immunogenicity, and overcoming barriers in genome editing. Recent advancements, challenges, and therapeutic applications are explored,
Elizabeth Maria Clarissa, Mamata Karmacharya, Hyunmin Choi, Sumit Kumar, Yoon‐Kyoung Cho   +4 more
wiley   +1 more source